Drug-gene and drug-drug interactions associated with tramadol and codeine therapy in the INGENIOUS trial

Cathy R. Fulton, Yong Zang, Zeruesenay Desta, Marc Rosenman, Ann Holmes, Brian Decker, Yifei Zhang, John T Callaghan, Victoria M. Pratt, Kenneth Levy, Brandon T. Gufford, Paul Dexter, Todd Skaar, Michael Eadon

Research output: Contribution to journalArticle

Abstract

Background: Tramadol and codeine are metabolized by CYP2D6 and are subject to drug-gene and drug-drug interactions. Methods: This interim analysis examined prescribing behavior and efficacy in 102 individuals prescribed tramadol or codeine while receiving pharmaco-genotyping as part of the INGENIOUS trial (NCT02297126). Results: Within 60 days of receiving tramadol or codeine, clinicians more frequently prescribed an alternative opioid in ultrarapid and poor metabolizers (odds ratio: 19.0; 95% CI: 2.8-160.4) as compared with normal or indeterminate metabolizers (p = 0.01). After adjusting the CYP2D6 activity score for drug-drug interactions, uncontrolled pain was reported more frequently in individuals with reduced CYP2D6 activity (odds ratio: 0.50; 95% CI: 0.25-0.94). Conclusion: Phenoconversion for drug-drug and drug-gene interactions is an important consideration in pharmacogenomic implementation; drug-drug interactions may obscure the potential benefits of genotyping.

Original languageEnglish (US)
Pages (from-to)397-408
Number of pages12
JournalPharmacogenomics
Volume20
Issue number6
DOIs
StatePublished - Apr 1 2019

Fingerprint

Tramadol
Codeine
Drug Interactions
Cytochrome P-450 CYP2D6
Pharmaceutical Preparations
Genes
Therapeutics
Odds Ratio
Pharmacogenetics
Opioid Analgesics
Pain

Keywords

  • adverse side effects
  • CYP2D6
  • IGNITE
  • INGENIOUS
  • pharmacogenetics; opioids
  • pharmacogenomics
  • phenoconversion

ASJC Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Pharmacology

Cite this

Drug-gene and drug-drug interactions associated with tramadol and codeine therapy in the INGENIOUS trial. / Fulton, Cathy R.; Zang, Yong; Desta, Zeruesenay; Rosenman, Marc; Holmes, Ann; Decker, Brian; Zhang, Yifei; T Callaghan, John; Pratt, Victoria M.; Levy, Kenneth; Gufford, Brandon T.; Dexter, Paul; Skaar, Todd; Eadon, Michael.

In: Pharmacogenomics, Vol. 20, No. 6, 01.04.2019, p. 397-408.

Research output: Contribution to journalArticle

@article{1ee35748a1864c49b1ec998b54934fc4,
title = "Drug-gene and drug-drug interactions associated with tramadol and codeine therapy in the INGENIOUS trial",
abstract = "Background: Tramadol and codeine are metabolized by CYP2D6 and are subject to drug-gene and drug-drug interactions. Methods: This interim analysis examined prescribing behavior and efficacy in 102 individuals prescribed tramadol or codeine while receiving pharmaco-genotyping as part of the INGENIOUS trial (NCT02297126). Results: Within 60 days of receiving tramadol or codeine, clinicians more frequently prescribed an alternative opioid in ultrarapid and poor metabolizers (odds ratio: 19.0; 95{\%} CI: 2.8-160.4) as compared with normal or indeterminate metabolizers (p = 0.01). After adjusting the CYP2D6 activity score for drug-drug interactions, uncontrolled pain was reported more frequently in individuals with reduced CYP2D6 activity (odds ratio: 0.50; 95{\%} CI: 0.25-0.94). Conclusion: Phenoconversion for drug-drug and drug-gene interactions is an important consideration in pharmacogenomic implementation; drug-drug interactions may obscure the potential benefits of genotyping.",
keywords = "adverse side effects, CYP2D6, IGNITE, INGENIOUS, pharmacogenetics; opioids, pharmacogenomics, phenoconversion",
author = "Fulton, {Cathy R.} and Yong Zang and Zeruesenay Desta and Marc Rosenman and Ann Holmes and Brian Decker and Yifei Zhang and {T Callaghan}, John and Pratt, {Victoria M.} and Kenneth Levy and Gufford, {Brandon T.} and Paul Dexter and Todd Skaar and Michael Eadon",
year = "2019",
month = "4",
day = "1",
doi = "10.2217/pgs-2018-0205",
language = "English (US)",
volume = "20",
pages = "397--408",
journal = "Pharmacogenomics",
issn = "1462-2416",
publisher = "Future Medicine Ltd.",
number = "6",

}

TY - JOUR

T1 - Drug-gene and drug-drug interactions associated with tramadol and codeine therapy in the INGENIOUS trial

AU - Fulton, Cathy R.

AU - Zang, Yong

AU - Desta, Zeruesenay

AU - Rosenman, Marc

AU - Holmes, Ann

AU - Decker, Brian

AU - Zhang, Yifei

AU - T Callaghan, John

AU - Pratt, Victoria M.

AU - Levy, Kenneth

AU - Gufford, Brandon T.

AU - Dexter, Paul

AU - Skaar, Todd

AU - Eadon, Michael

PY - 2019/4/1

Y1 - 2019/4/1

N2 - Background: Tramadol and codeine are metabolized by CYP2D6 and are subject to drug-gene and drug-drug interactions. Methods: This interim analysis examined prescribing behavior and efficacy in 102 individuals prescribed tramadol or codeine while receiving pharmaco-genotyping as part of the INGENIOUS trial (NCT02297126). Results: Within 60 days of receiving tramadol or codeine, clinicians more frequently prescribed an alternative opioid in ultrarapid and poor metabolizers (odds ratio: 19.0; 95% CI: 2.8-160.4) as compared with normal or indeterminate metabolizers (p = 0.01). After adjusting the CYP2D6 activity score for drug-drug interactions, uncontrolled pain was reported more frequently in individuals with reduced CYP2D6 activity (odds ratio: 0.50; 95% CI: 0.25-0.94). Conclusion: Phenoconversion for drug-drug and drug-gene interactions is an important consideration in pharmacogenomic implementation; drug-drug interactions may obscure the potential benefits of genotyping.

AB - Background: Tramadol and codeine are metabolized by CYP2D6 and are subject to drug-gene and drug-drug interactions. Methods: This interim analysis examined prescribing behavior and efficacy in 102 individuals prescribed tramadol or codeine while receiving pharmaco-genotyping as part of the INGENIOUS trial (NCT02297126). Results: Within 60 days of receiving tramadol or codeine, clinicians more frequently prescribed an alternative opioid in ultrarapid and poor metabolizers (odds ratio: 19.0; 95% CI: 2.8-160.4) as compared with normal or indeterminate metabolizers (p = 0.01). After adjusting the CYP2D6 activity score for drug-drug interactions, uncontrolled pain was reported more frequently in individuals with reduced CYP2D6 activity (odds ratio: 0.50; 95% CI: 0.25-0.94). Conclusion: Phenoconversion for drug-drug and drug-gene interactions is an important consideration in pharmacogenomic implementation; drug-drug interactions may obscure the potential benefits of genotyping.

KW - adverse side effects

KW - CYP2D6

KW - IGNITE

KW - INGENIOUS

KW - pharmacogenetics; opioids

KW - pharmacogenomics

KW - phenoconversion

UR - http://www.scopus.com/inward/record.url?scp=85066471601&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066471601&partnerID=8YFLogxK

U2 - 10.2217/pgs-2018-0205

DO - 10.2217/pgs-2018-0205

M3 - Article

C2 - 30784356

AN - SCOPUS:85066471601

VL - 20

SP - 397

EP - 408

JO - Pharmacogenomics

JF - Pharmacogenomics

SN - 1462-2416

IS - 6

ER -